Sarin B, Bindhu B, Saju B, Nair Raguram K
Department of Physics, Noorul Islam Centre For Higher Education, Kumaracoil, Kanyakumari, Tamil Nadu, India.
Division of Radiation Physics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India.
J Med Phys. 2020 Jan-Mar;45(1):24-35. doi: 10.4103/jmp.JMP_75_19. Epub 2020 Mar 13.
This study aims to model 6MV photon of ClinaciX linear accelerator using PRIMO Monte Carlo (MC) code and to assess PRIMO as an independent MC-based dose verification and quality assurance tool.
The modeling of ClinaciX linear accelerator has been carried out by using PRIMO simulation software (Version 0.3.1.1681). The simulated beam parameters were compared against the measured beam data of the ClinaciX machine. The PRIMO simulation model of ClinaciX was also validated against Eclipse Acuros XB dose calculations in the case of both homogenous and inhomogeneous mediums. The gamma analysis method with the acceptance criteria of 2%, 2 mm was used for the comparison of dose distributions.
Gamma analysis shows a minimum pass percentage of 99% for depth dose curves and 95.4% for beam profiles. The beam quality index and output factors and absolute point dose show good agreement with measurements. The validation of PRIMO dose calculations, in both homogeneous and inhomogeneous medium, against Acuros XB shows a minimum gamma analysis pass rate of 99%.
This study shows that the research software PRIMO can be used as a treatment planning system-independent quality assurance and dose verification tool in daily clinical practice. Further validation will be performed with different energies, complex multileaf collimators fields, and with dynamic treatment fields.
本研究旨在使用PRIMO蒙特卡罗(MC)代码对ClinaciX直线加速器的6MV光子进行建模,并评估PRIMO作为一种基于MC的独立剂量验证和质量保证工具。
使用PRIMO模拟软件(版本0.3.1.1681)对ClinaciX直线加速器进行建模。将模拟的射束参数与ClinaciX机器的实测射束数据进行比较。在均匀和非均匀介质的情况下,还针对Eclipse Acuros XB剂量计算对ClinaciX的PRIMO模拟模型进行了验证。采用接受标准为2%、2mm的伽马分析方法来比较剂量分布。
伽马分析显示,深度剂量曲线的最小通过率为99%,射野轮廓的最小通过率为95.4%。射束质量指数、输出因子和绝对点剂量与测量结果显示出良好的一致性。在均匀和非均匀介质中,PRIMO剂量计算相对于Acuros XB的验证显示伽马分析的最小通过率为99%。
本研究表明,研究软件PRIMO可在日常临床实践中用作独立于治疗计划系统的质量保证和剂量验证工具。将使用不同能量、复杂的多叶准直器射野以及动态治疗射野进行进一步验证。